ACTH 1-17 effects in the chemotherapy of advanced solid tumors.

Abstract

The effect of administration of a synthetic ACTH analogue (ACTH 1-17, Synchrodyn) in the chemotherapy of advanced-phase solid tumors was studied. In this preliminary report the following data are evaluated: response rate; occurrence of toxic effects; performance status of patients; several immunological parameters. The administration of Synchrodyn seems mainly to influence the lymphocyte subpopulations and the occurrence of toxic effects. A final evaluation of the role that may be played by chronotherapy in the treatment of tumors must await further studies on the clinical response and tolerance.

• Authors: C Barone, A Grieco, A Astone, L Vagliviello, C Garufi, A V Greco
• Journal: La Ricerca in clinica e in laboratorio (Ric Clin Lab) 1984 Apr-Jun Vol. 14 Issue 2 Pg. 211-20 ISSN: 0390-5748 [Print] Italy
• PMID: 6091246 (Publication Type: Journal Article)

Chemical References

• Peptide Fragments
• Adrenocorticotropic Hormone
• ACTH (1-17)

Topics

• Adrenocorticotropic Hormone (pharmacology, therapeutic use)
• Circadian Rhythm (drug effects)
• Drug Administration Schedule
• Drug Therapy, Combination
• Humans
• Immunity (drug effects)
• Lymphocytes (drug effects)
• Neoplasms (drug therapy)
• Peptide Fragments (pharmacology, therapeutic use)